| Drug Type AAV based gene therapy | 
| Synonyms AAV9 gene therapy containing codon optimized human FIG4 cDNA coding sequence (Elpida Therapeutics), AAV9-hFIG4 (Elpida Therapeutics), Elpida 02 | 
| Target | 
| Action modulators | 
| Mechanism FIG4 modulators(FIG4 phosphoinositide 5-phosphatase modulators) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| RegulationOrphan Drug (United States) | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Charcot-Marie-Tooth Disease, Type 4j | Preclinical | United States  | 08 Oct 2023 | 





